Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Half Of Breakthrough Designations Have Resulted In Approval

<< Previous

Bullboard Posts

Next >>

Comment by LaserStock29on Apr 27, 2022 4:24pm

159 Views

Post# 34636840

RE:RE:RE:RE:RE:RE:RE:RE:Half Of Breakthrough Designations Have Resulted In Approval

So until then just fill the gap.. let the flippers reload under .30 rinse and repeat since 2014.. bravo.. lets get some more posts on presentations, science and other buillshi*

Rumpl3StiltSkin wrote: Yep Laser, EoY. Yet maybe they'll give us a good PR when they've sent in the paperwork? That could happen this Summer?? 60 day clock will then start and if the numbers are as good as Keytruda's then should be an easy lift.

LaserStock29 wrote: Well then, it's all bow tied up then..... no BTD until EOY basically.. So what are the catalysts.. patient checks?

https://stockhouse.com/companies/bullboard/v.tlt/theralase-technologies-inc?postid=34545532

Patient #16 hits 1 year this Friday March 25th
Patients # 17 & 18 hit 1 year April 27
Patient # 19 on May 28th for 1 year
June 11th is patient # 20's 1 year.

Eoganacht wrote: According to the projected timeline on slide 12 of the corporate presentation, Theralase is shooting for BTD in the last quarter of 2022 followed immediately by the beginning of the commercialization phase in the first quarter of 2023. If the FDA requires 60 days to respond to a BTD application then it looks like Theralase plans to apply in the third quarter or beginning of the fourth quarter 2022.

Rumpl3StiltSkin wrote: True, Good discussion guys. The issue is we don't know one way or the other if the BTD has been requested? It may not have been prior to the last PR, but it may have?? Or, if more data has come out since then, maybe it has now been requested? Or maybe in a week or two, or a month... 60 days after we should know, right?

FGPstock wrote:
Laser, while i don't typically agree w bencro. BTD still needs to be requested even if you have been approved for fast track as fast track has a lower threshold for approval. Most companies initially apply for Fast Track designation and later submit a request for Breakthrough Therapy designation as development progresses. As far as I know, TLT has not made the BTD request yet, at least they have not made it public. Once the request is made they have 60 days to respond and BTD also has a rolling review. I am far from an expert, but just because there is a rolling review for FT, that doesn't automatically give you rolling review for BTD w o the appropriate request. Sorry, my highlighter isn't working today :)